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Protocol
AbstrACt
Introduction In an increasingly digital age for healthcare 
around the world, administrative data have become 
rich and accessible tools for potentially identifying and 
monitoring population trends in diseases including 
epilepsy. However, it remains unclear (1) how accurate 
administrative data are at identifying epilepsy within a 
population and (2) the optimal algorithms needed for 
administrative data to correctly identify people with 
epilepsy within a population. To address this knowledge 
gap, we will conduct a novel systematic review of all 
identified studies validating administrative healthcare 
data in epilepsy identification. We provide here a protocol 
that will outline the methods and analyses planned for the 
systematic review.
Methods and analysis The systematic review described 
in this protocol will be conducted to follow the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. MEDLINE and Embase 
will be searched for studies validating administrative 
data in epilepsy published from 1975 to current (01 June 
2018). Included studies will validate the International 
Classification of Disease (ICD), Ninth Revision (ICD-9) 
onwards (ie, ICD-9 code 345 and ICD-10 codes G40–G41) 
as well as other non-ICD disease classification systems 
used, such as Read Codes in the UK. The primary outcome 
will be providing pooled estimates of accuracy for 
identifying epilepsy within the administrative databases 
validated using sensitivity, specificity, positive and negative 
predictive values, and area under the receiver operating 
characteristic curves. Heterogeneity will be assessed using 
the I2 statistic and descriptive analyses used where this 
is present. The secondary outcome will be the optimal 
administrative data algorithms for correctly identifying 
epilepsy. These will be identified using multivariable 
logistic regression models. 95% confidence intervals will 
be quoted throughout. We will make an assessment of risk 
of bias, quality of evidence, and completeness of reporting 
for included studies.
Ethics and dissemination Ethical approval is not 
required as primary data will not be collected. Results will 
be disseminated in peer-reviewed journals, conference 
presentations and in press releases.
PrOsPErO registration CRD42017081212.
IntrOduCtIOn 
Administrative healthcare databases are 
electronic data sources that consist of demo-
graphic, diagnostic and clinical information 
routinely collected about patients when they 
use a healthcare service.1 They are often 
national and mandatory, and therefore they 
have the potential to provide a relatively 
cheap, widely available and less intrusive 
resource for medical research.1 However, 
the accuracy of the information held in an 
administrative database needs to be validated 
before such use can be made. This is because 
the administrative data were not originally 
collected for research, but for other purposes 
such as assisting in health insurance claims. 
The clinical information held may there-
fore lack the rigour in accuracy that might 
be expected in scientifically collected data. 
strengths and limitations of this study
 ► The protocol describes what will be the first sys-
tematic review to conduct a worldwide assessment 
of the accuracy of administrative data in identify-
ing epilepsy and the optimal disease-identification 
algorithms.
 ► This protocol also describes what will be the first 
systematic review to make an assessment of risk 
of bias, quality of evidence, and completeness of re-
porting for studies validating administrative health-
care data in epilepsy identification.
 ► The review described in this protocol will be limited 
to assessing the use of administrative data in diag-
nosing epilepsy within observational studies, which 
are more prone to bias than randomised controlled 
trials.
 ► A systematic review of the diagnostic accuracy of 
administrative data within randomised controlled 
trials in epilepsy remains to be completed and is out 
of the scope of the current review.
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Furthermore, the data may be limited by inaccurate or 
incomplete hospital discharge letters or clinical coding 
transcription errors.2 
The validation of administrative data involves 
comparing the diagnostic codes held within the admin-
istrative database against a reference standard (such as 
medical records) in order to quantify the number of 
instances in which the administrative diagnosis made 
matches the diagnosis in the reference standard (deemed 
to be the true diagnosis). In this way, the administra-
tive database can be handled like a diagnostic test and 
measures of disease-identification accuracy calculated. 
These measures usually include the sensitivity, specificity 
and the positive or negative predictive value (PPV or NPV, 
respectively). Optimal disease-identification algorithms 
can also be determined by making relative comparisons 
of predictive values after adding in data from other vari-
ables recorded in an administrative database, such as 
drug combinations, investigations, and procedures.
There are many administrative databases worldwide 
in which the process of validation has been successfully 
performed for many diagnostic codes.3–9 There are also 
examples of where the results of these have been pooled 
successfully into systematic review to increase confidence in 
the estimates made and scrutinise the quality of evidence, 
and this has led to changes in practice.4 There has been 
limited systematic review of the validation of administra-
tive databases in capturing epilepsy as a diagnosis. The 
only systematic review10 on this subject included only 
studies from the USA or Canada and therefore excluded 
121 studies because the data sources were not from these 
two countries. Furthermore, the 11 studies included were 
published between 2000 and 2010, making the conclu-
sions nearly a decade old now. With health informatics 
now at the forefront of epidemiological disease surveil-
lance, it is important to have an update on performance 
of the administrative disease-identification codes. Only 
one of the included studies evaluated the performance 
of the International Classification of Disease (ICD), 10th 
Revision (ICD-10) system in capturing epilepsy within 
administrative datasets11; the remainder evaluated the 
older ICD, 9th Revision (ICD-9) system.10 The review also 
made no assessment of risk of bias, quality of evidence 
and completeness of reporting for included studies. This 
limits the confidence with which conclusions can be 
interpreted. There is now need for a more contempo-
rary systematic review of the validation of administrative 
databases in capturing epilepsy. This should include eval-
uating performance of the ICD-10 system, as well as other 
non-ICD disease classification systems used, such as Read 
Codes in the UK.12 13 The review should include studies 
from anywhere in the world in order to give clinicians and 
researchers a representative picture of the performance 
of administrative data in capturing epilepsy as a diagnosis 
and in order to allow more generalisable diagnostic algo-
rithms to be suggested. Furthermore, the review should 
make an assessment of risk of bias, quality of evidence and 
completeness of reporting for included studies. These are 
the aims of the proposed systematic review described in 
this protocol. This will help researchers and clinicians 
better understand the accuracy of global estimates for 
incidence, prevalence and population characteristics in 
epilepsy, which have largely been made using administra-
tive data.
Aims and objectives
The study hypotheses are:
1. Administrative data can correctly identify people with 
epilepsy within a population with a high degree of ac-
curacy. We predict the PPV to be above 80%.
2. The optimal disease-identification algorithms for epi-
lepsy within administrative datasets take into account 
diagnoses, investigations and drug combinations.11 14–20
The aim of the systematic review is to quantify the 
disease-identification accuracy and algorithm perfor-
mance of administrative healthcare data in epilepsy. To 
this end, the research questions are:
1. How accurately do administrative data identify epilep-
sy within a population as measured by sensitivity, spec-
ificity, PPV, NPV, or area under the receiver operating 
characteristic curve (AUC) analysis (which are the ap-
proved accuracy measures described in the Standards 
for Reporting Diagnostic Accuracy (STARD) state-
ment)?21 This will be the primary outcome.
2. What are the optimal administrative data algorithms 
for correctly identifying epilepsy within a population? 
This will be the secondary outcome.
A preliminary feasibility search of the MEDLINE data-
base via PubMed identifies at least nine studies validating 
diagnostic epilepsy codes held within administrative data-
bases around the world that could be used to answer these 
research questions.11 13–20
MEthOds And AnAlysIs
This protocol follows the Preferred Reporting Items for 
Systematic Review and Meta-Analysis Protocols (PRIS-
MA-P) checklist.22 23 The systematic review will follow the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist.24
Eligibility criteria
We will include studies according to the following criteria:
Language: there will be no language restriction on full-
length articles, although abstracts will need to be in 
English to allow the authors to screen them. We will 
seek translations for full-length articles not written in 
English that appear eligible in abstract. These will re-
main in the section for ‘studies still awaiting classifica-
tion’ and will feature in subsequent updates to the re-
view if not translated by the time of initial publication.
Setting: there will be no restrictions by study location 
worldwide. Where possible, we will show pooled accu-
racy and best algorithm data for administrative data-
sets from individual countries in addition to pooled 
global estimates of these measures.
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Databases: the data sources will be routine administra-
tive healthcare databases. This means that the data 
should have been routinely and passively collected 
without an a priori research question.4 We will include 
databases containing diagnostic codes for epilepsy 
classified on the ICD system, where we will restrict this 
to studies using the ICD-9 onwards (active from 1975 
to 1994).25 This is because although the ICD system 
is currently in its 10th revision (ICD-10; active from 
1994 to present) and the primary coding system is 
used by many countries around the world, a signifi-
cant proportion of countries, particularly developing 
ones, still use the ICD-9 system.11 ICD-9 code 345 and 
ICD-10 codes G40 and or G41 will be used to identi-
fy epilepsy diagnoses. We will provide summary mea-
sures of accuracy and best algorithms for any other 
disease classification systems used in studies separate-
ly, for example, the primary care Read Code system 
used in the UK.12 13
Study design: prospective or retrospective observation-
al studies including cohort or case–control designs 
that are community-based/population-based or pri-
mary/secondary/tertiary care-based and have used 
administrative databases.
Participants: people with epilepsy of all ages. Where 
available, we will additionally report data for adults 
and children separately.
Observations and outcomes: studies will need to employ 
a validation process for diagnostic epilepsy codes, that 
is, estimate the disease-identification accuracy of the 
epilepsy codes held within the database using sensi-
tivity, specificity, PPV, NPV or AUC analysis.21 In this, 
true positives (TPs) and false negatives (FNs) will be 
considered as the patient has the disease and the ad-
ministrative diagnosis is positive or negative, respec-
tively. True negatives (TNs) and false positives (FPs) 
will be considered as the patient does not have the 
disease and the administrative diagnosis is negative 
or positive, respectively. Sensitivity will be considered 
as the ability of the administrative database to cor-
rectly identify those patients with the disease (TP/
(TP+FN)). Specificity will be considered as the abili-
ty of the administrative database to correctly identify 
those patients without the disease (TN/(TN+FP)). 
PPV will be considered as how likely it is that a pa-
tient has the disease if the administrative diagnosis 
is positive (TP/(TP+FP)). NPV will be considered as 
how likely it is that this patient does not have the dis-
ease if the administrative diagnosis is negative (TN/
(TN+FN)). AUC analysis will be considered as where 
TP and FP are plotted against each other in a perfect 
correlation as reference to show poor test accuracy, 
then accuracy measured as the area under the curve 
created by plotting the actual values against each oth-
er.26
Studies may also use diagnostic as well as other vari-
ables (eg, admissions, drugs or investigations) to 
calculate optimal disease-identification algorithms 
for epilepsy within the database. Studies will need to 
provide a clinical reference standard. An appropriate 
clinical reference standard will be medical records, 
clinical assessment, or a validated disease registry.21
Timeframe: studies conducted from 1 January 1975 to 
01 June 2018. The year 1975 represents the advent of 
ICD-9.25
We will exclude studies according to the following 
criteria:
Data reported in systematic reviews unless we can 
identify the primary data, for example, by contacting 
authors of the original source.
Conference proceedings abstracts or studies not writ-
ten in English where we are unable to obtain the me-
ta-data from authors or full-length manuscript transla-
tions remain awaited, respectively.
Information sources
Studies will be identified from the following sources
 ► Electronic databases: we will search 01 January 1975–01 
June 2018 for studies meeting the inclusion criteria 
within the MEDLINE (Ovid interface) and Embase 
(Ovid interface) databases. The search strategies are 
outlined in table 1.
 ► Conference proceedings: for conference abstracts that 
appear to meet the inclusion criteria but do not have 
a full-length article published, we will contact authors 
directly to request metadata.
 ► Reference lists: we will also identify studies meeting the 
inclusion criteria from the reference lists of included 
studies and relevant reviews identified through the 
electronic database searches.
study records
Data management
Literature search results will be uploaded onto Review 
Manager 5, an internet-based software program that facil-
itates collaboration among reviewers. Citation titles and 
abstracts will be uploaded. GKM will then screen titles and 
abstracts to identify and exclude duplicate publications. 
Duplicate publications will be identified by comparing 
author names, study titles, sample sizes, outcomes used, 
and any other information held in the abstracts. All 
reviewer authors will have access to the systematic review 
process via the internet-based review software program, 
and this will create an audit trail of studies included/
excluded, data analysis steps, and subsequent manuscript 
revisions. All data will be held within the management 
software and password protected.
Selection process
Once duplicates have been excluded, two review authors 
(GKM and KB) will independently screen the titles and 
abstracts yielded from the databases searches against the 
inclusion criteria. Where titles and abstracts indicate that 
a study may meet the inclusion criteria or where there is 
uncertainty about this, the full-length manuscripts will be 
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downloaded and used to help decide. Where details in 
the manuscript are still insufficient for a decision to be 
made about eligibility, we will seek additional information 
from the study authors and automatically exclude studies 
where there is no response from authors after three weeks. 
We will record the reasons for excluding all excluded 
studies. The two review authors will compare their list 
of included and excluded trials and any disagreements 
Table 1 Search strategies for MEDLINE and Embase
Ovid MEDLINE Epub Ahead of Print, In-Process & Other 
Non-Indexed Citations, Ovid MEDLINE Daily and Ovid 
MEDLINE 1946 to 01 June 2018 Embase 1974 to 01 June 2018
1. Epilepsy, Complex Partial/or Epilepsy, Reflex/or Epilepsy, 
Absence/or Drug Resistant Epilepsy/or Epilepsy/
or Epilepsy, Rolandic/or Epilepsy, Partial, Motor/or Epilepsy, 
Benign Neonatal/or Epilepsy, Tonic-Clonic/or Epilepsy, 
Post-Traumatic/or Epilepsy, Partial, Sensory/or Epilepsy.
mp. or Epilepsy, Temporal Lobe/or Epilepsy, Frontal Lobe/
or Myoclonic Epilepsy, Juvenile/or Epilepsy, Generalized/
2. Databases, Factual/
3. ‘Reproducibility of Results’/
4. Algorithms/or algorithm*.mp.
5. 3 or 4
6. 2 and 5
7. 1 and 6
8. Administrative Claims, Healthcare/or administrativ*.mp. 
or insurance data*.mp. or claims data*.mp. or Veterans 
Health Administration.mp.
9. administrat* data*.mp.
10. routin* data*.mp.
11. big data.mp.
12. 8 or 9 or 10 or 11
13. 1 and 12
14. Algorithms/or algorithm*.mp.
15. ‘Sensitivity and Specificity’/or ‘Predictive Value of Tests’/
or predictive value.mp.
16. positive* predict* value*.mp.
17. negative* predict* value*.mp.
18. sensitivity.mp.
19. specificity.mp.
20. area* under* curve*.mp. or Area Under Curve/
21. ROC Curve/or ROC curve*.mp.
22. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. code*.mp.
24. (ICD-9 or ICD-10).mp. or ‘International Classification of 
Diseases’/or Clinical Coding/or read code*.mp.
25. 23 or 24
26. 22 and 25
27. 1 and 26
28. (validat* or validity).mp. or Validation Studies/
29. Medical Records/or medical record*.mp. or medical case 
note*.mp.
30. electronic health records.mp. or Medical Records 
Systems, Computerized/or Electronic Health Records/
31. Registries.mp. or Registries/
32. 29 or 30 or 31
33. 28 and 32
34. 1 and 33
35. 7 or 13 or 27 or 34
36. limit 35 to yr=‘1975 -Current’
37. Animals/not Humans/
38. 36 not 37
1. reflex epilepsy/or photosensitive epilepsy/or grand mal 
epilepsy/or epilepsy.mp. or drug resistant epilepsy/
or experimental epilepsy/or severe myoclonic epilepsy in 
infancy/or childhood absence epilepsy/or benign childhood 
epilepsy/or catamenial epilepsy/or symptomatic epilepsy/
or startle epilepsy/or generalized epilepsy/or epilepsy/
or mesial temporal lobe epilepsy/or rolandic epilepsy/
or traumatic epilepsy/or myoclonic astatic epilepsy/
or temporal lobe epilepsy/or intractable epilepsy/
or focal epilepsy/or ‘seizure, epilepsy and convulsion’/
or myoclonus epilepsy/or lateral temporal lobe epilepsy/
or frontal lobe epilepsy/
2. factual database/or data base/
3. reproducibility/
4. algorithm/or algorithm*.mp.
5. 3 or 4
6. 2 and 5
7. 1 and 6
8. ‘administrative claims (health care)"/or administrative*.mp. 
or insurance data*.mp. or claims data*.mp. or Veterans 
Health Administration.mp.
9. administrat* data*.mp.
10. routin* data*.mp.
11. big data.mp.
12. 8 or 9 or 10 or 11
13. 1 and 12
14. algorithm/or algorithm*.mp.
15. (specificity or sensitivity).mp. or ‘sensitivity and specificity’/
or positive* predict* value*.mp. or negative* predict* value*.
mp.
16. area under the curve/or area* under* curve*.mp.
17. roc curve/or receiver operating characteristic/or ROC 
curve*.mp.
18. 14 or 15 or 16 or 17
19. code*.mp. or ‘Read code’/
20. ICD-10.mp. or ‘International Classification of Diseases’/or 
ICD-10/or disease classification/or ICD-9.mp. or ICD-9/
21. 19 or 20
22. 18 and 21
23. 1 and 22
24. validation study/or validation Process/or validat*.mp. or 
validity/or predictive validity/or validity.mp.
25. electronic medical record/or medical record/or medical 
record*.mp. or medical case note*.mp.
26. Registries.mp. or register/
27. 25 or 26
28. 24 and 27
29. 1 and 28
30. 7 or 13 or 23 or 29
31. limit 30 to yr=‘1975 -Current’
32. animal/not human/
33. 31 not 32
 o
n
 20 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020824 on 30 June 2018. Downloaded from 
5Mbizvo GK, et al. BMJ Open 2018;8:e020824. doi:10.1136/bmjopen-2017-020824
Open access
will be resolved by mutual discussion and, where neces-
sary, adjunction by a third reviewer (RFMC/SED/CRS). 
Review authors will not be blind to the journal titles, study 
authors, or institutions.
Data collection process and items
Two review authors (GKM and KB) will independently 
abstract data about the primary and secondary outcomes 
from included studies using the data collection tool 
shown below. The additional information extracted maps 
onto the items contained within the STARD guidelines 
modified for epilepsy studies reporting diagnostic accu-
racy of administrative databases.21 This will allow us to 
extract sufficient information to make a quality assess-
ment of the completeness of included studies against the 
STARD checklist.21 Any disagreements in the contents of 
data abstraction will be resolved by mutual discussion and, 
where necessary, adjunction by a third reviewer (RFMC/
SED/CRS).
data collection tool
 ► What is the study title?
 ► Who are the study authors?
 ► What is the year of study publication?
 ► What is the journal of publication?
 ► What country(s) was the study conducted in?
 ► Does the study explicitly identify as utilising ‘adminis-
trative data’ (yes/no)?
 – If not, how is this identified by the reviewer? For 
example, from descriptions given of the databases 
utilised and background knowledge about them or 
from correspondence with authors.
 ► Does the abstract provide a structured summary of 
study design, methods, results and conclusions (yes/
no/unclear)?
 ► Does the introduction give a scientific and clinical 
background including intended use and clinical role 
of administrative data (yes/no/unclear)?
 ► Are the study objectives and hypotheses described 
(yes/no/unclear)?
 – If so, what are they?
 ► What was the intended study sample size and how was 
it determined?
 ► What is the study design?
 ► Was a study/participant flow diagram used?
 ► What are the eligibility criteria for participation in the 
validation cohort (ie, the cohort of patients to which 
the reference standard will be applied)?
 ► Where, when and how were potentially eligible vali-
dation cohort participants identified? Include within 
this:
 – What is the name of the administrative database(s) 
on which the validation cohort was identified?
 – What are the setting and location of the adminis-
trative database(s) from which the validation co-
hort was identified? For example, is it primary care, 
secondary care, tertiary care, outpatient care and 
emergency care?
 – What are the names of any hospitals/organisations 
affiliated with or using the administrative database 
routinely?
 – What is the size of the administrative database(s) 
on which the validation cohort was identified? That 
is, how many people/records does it hold in total?
 – What were the epilepsy ICD codes (or other dis-
ease classification system codes) used to identify 
the validation cohort within the administrative da-
tabase(s)? That is, what are the diagnostic epilepsy 
codes that will be validated by the study?
 – What was the size of the validation cohort identi-
fied by the epilepsy codes? That is, give the number 
of participants identified by these diagnostic epi-
lepsy codes.
 – Did the validation cohort include identifying a 
sample of people (1) without epilepsy and (2) with 
epilepsy ‘mimicker codes’?
 – If so, give details of the codes used and the num-
ber of participants for each of these groups.
 – Samples of people without epilepsy are often 
used to help calculate the specificity and NPV 
of an administrative database. ‘ Mimicker codes’ 
are often interrogated as the conditions may re-
semble epilepsy. These may include, for exam-
ple, classical migraine (ICD-9 code 346.x and 
ICD-10 code G43.1), transient cerebral ischa 
emia (ICD-9 code 435 and ICD-10 code G45), 
syncope (ICD-9 code 780.2 and ICD-10 code 
R55) or convulsion (ICD-9 code 780.3 and ICD-
10 code R56.0 or R56.8), which are intended to 
be used for organic convulsions but not for ep-
ilepsy.11 
 ► What other information was obtained about an indi-
vidual to help identify epilepsy on the administrative 
database? For example, describe if they linked an 
individual’s ICD epilepsy codes with the investigations 
they underwent (such as an electroencephalogram 
(EEG)) or the antiepileptic drug (AED) they were 
taking.
 ► What were the demographic and clinical characteris-
tics of the validation cohort? That is, age, gender, type 
of epilepsy, comorbidities and AEDs.
 ► Describe the reference standard. Include the 
following:
 – Name of the reference standard used.
 – What type of reference standard it was, for exam-
ple, clinical assessment, medical records, or validat-
ed disease registry.
 – Any rational given for choosing this reference stan-
dard (if alternatives exist).
 – What were the number, training and expertise of 
persons reading the reference standard?
 – If more than one person read the reference stan-
dard, what were the measures of consistency given? 
For example, kappa statistic.
 ► Describe any methods used to blind persons reading 
the reference standard to how the validation cohort 
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were coded diagnostically on the administrative data-
base; that is, how a person reviewing the medical 
records diagnosis of an individual was made unaware 
of their administrative ICD diagnosis.
 ► Describe any methods used to blind persons reading 
the diagnostic administrative data codes to results of 
the reference standard diagnoses.
 ► What method was used to estimate the disease-iden-
tification accuracy of the administrative database (ie, 
sensitivity, specificity, PPV, NPV or AUC)?
 – What were the results of this?
 – That is, provide figures for these estimates and, 
where possible, also the individual TP, FP, TN 
and FN figures.
 – Include the results of any cross-tabulation of the 
administrative data diagnoses results against the 
results of the reference standard diagnoses.
 – Describe the methods used and results of the 
measures used to estimate variability or preci-
sion of the diagnostic accuracy results (eg, 95% 
CI).
 ► What method was used to compare the diagnostic 
accuracy of variables within the administrative data-
base? That is, describe the method used to determine 
an optimal diagnostic algorithm.
 – What were the results of this?
 – Describe the methods used and results of the mea-
sures used to estimate variability or precision of the 
algorithm estimates (eg, 95% CI).
 ► How were indeterminate or missing administrative 
database diagnoses or reference standard results 
handled?
 ► What were the time interval and any clinical interven-
tions given between reference standard diagnosis and 
administrative database diagnosis?
 ► Describe any adverse events found from using the 
administrative database or reference standard.
 ► Summarise the study limitations described by the 
authors including any sources of potential bias, statis-
tical uncertainty, generalisability limitation, and what 
they described as implications for practice.
 ► What were the study’s sources of funding?
systematic review and meta-analysis outcomes
The primary outcome will be providing pooled 
disease-identification accuracy estimates of the included 
administrative databases using sensitivity, specificity, PPV, 
NPV and AUC as the measures of accuracy. This will 
answer research question 1: how accurately do admin-
istrative data identify epilepsy within a population? We 
will provide an overall estimate of the accuracy of the 
ICD-9 coding system and that of the ICD-10 coding 
system in correctly identifying epilepsy cases. This will 
be done by pooling together individual accuracy esti-
mates from all included studies in which ICD-9 or ICD-10 
were used provided there is no significant heterogeneity 
between studies (as measured using the I2 statistic). The 
preferred estimators will be means with standard errors 
(SEs) or medians with interquartile ranges (IQRs), 
dependent on distribution. We will also quote the 95% 
CIs for estimates. Where there is significant heteroge-
neity (I2 statistic >50%), we will provide a descriptive 
analysis of the results and include ranges. Just as there 
may be heterogeneity introduced by making compari-
sons across different trial designs, we might expect there 
to be heterogeneity introduced by making comparisons 
across different healthcare systems. This is because there 
are likely to be differences in the accuracy of administra-
tive healthcare data owing to differences in coding prac-
tice and/or the quality of reference standards between 
different healthcare systems. Therefore, we will also 
conduct subgroup analysis in which diagnostic accuracy 
results are pooled together for studies that have used 
the same or similar healthcare systems, for example, 
the National Health Service in the UK, Veterans Health 
Administration in the USA, healthcare systems with 
geographical overlap, and private-funded versus state-
funded healthcare systems. We will also create subgroups 
in which results are pooled together within the following 
study design groups: prospective cohorts, retrospec-
tive cohorts, case–control studies, primary care studies, 
secondary care studies, tertiary care studies, paediatric 
studies (age <18 years), adult studies, and studies from 
the same country. Differences in the results for each 
subgroup may provide an important guide for future 
studies in the field, and they may also help to explain any 
statistical heterogeneity seen.
The secondary outcome will be the optimal adminis-
trative data algorithms for correctly identifying epilepsy 
within a population. For this, we will assign a dummy 
variable with a binary 0 = ‘no’ or 1 = ‘yes’ category to 
participants having the following:
A. A reference standard diagnosis of epilepsy (yes/no).
B. An administrative diagnosis code for epilepsy (yes/
no).
C. Multiple administrative epilepsy diagnoses codes over 
time (yes/no).
D. Having previously had an EEG (yes/no).
E. Having previously had a computed tomography (CT) 
or magnetic resonance image (MRI) of the brain 
(yes/no).
F. Having previously had epilepsy surgery (yes/no);
G. Being on an individual AED (yes/no).
H. Being on two or more AEDs (yes/no).
Multivariable logistic regression models with A as the 
outcome variable and B–H individually and in combi-
nations as the independent variables will be used in 
order to demonstrate the algorithm(s) best fitting the 
data across the included studies and to assess the signifi-
cance of each variable’s contribution to the model. The 
results of the logistic models will be displayed as sensi-
tivity, specificity, PPV, NPV and AUC where possible, 
with 95% CIs and measures of interstudy heterogeneity 
provided using the I2 statistic.
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risk of bias analysis
We will use the Quality Assessment of Diagnostic Accu-
racy Studies 2 (QUADAS-2)27 tool to assess risk of bias 
within and across studies, modified for studies validating 
administrative data. This is summarised in the table 2 
and will be completed independently by two review 
authors (GKM and KB) for each study, with disagree-
ments resolved by mutual discussion and, where neces-
sary, adjunction by a third reviewer (RFMC/SED/
CRS). The tool consists of four key domains (see row 
1) covering: (1) patient selection, (2) the administra-
tive database, (3) the reference standard and (4) flow 
of patients through the study and timing of the adminis-
trative database and reference standard. Each domain is 
assessed in terms of the risk of bias (graded as high, low 
or unclear; see row 4) and the first three domains are 
also assessed in terms of concerns regarding applica-
bility (see row 5). The description (see row 2) contains 
information used to support the risk of bias judgement. 
To help reach a judgement on the risk of bias, signalling 
questions are included (see row 3). These flag aspects 
of study design related to the potential for bias and aim 
to help reviewers make risk of bias judgements. If all 
signalling questions for a domain are answered ‘yes’, 
then risk of bias is judged ‘low’. If any signalling ques-
tion is answered ‘no’, then risk of bias is judged ‘high’. 
If any signalling question is answered ‘unclear’, then 
risk of bias is judged ‘unclear’. Applicability sections are 
structured in a similar way to the bias sections but do not 
include signalling questions. Review authors are asked 
Table 2 Risk of bias and applicability judgements in QUADAS-2
Domain Patient selection
Administrative 
database Reference standard Flow and timing
Description Describe methods of 
patient selection:
what is the review 
question?
Describe the 
administrative database 
and how it was used and 
interpreted:
where available, include 
comment on how coding 
was done, by whom 
and whether there was 
reimbursement for 
coding.
Describe the reference 
standard and how it 
was conducted and 
interpreted:
where available, 
include comment on 
quality of the reference 
standard, including the 
level of experience of 
clinicians making the 
diagnosis, access to 
diagnostic tests such as 
electroencephalography 
and telemetry and the 
thresholds/criteria used 
to make a diagnosis of 
epilepsy.
Describe any patients in 
the validation cohort who 
were not found within 
the reference standard 
or who were excluded 
from cross-tabulation 
of the administrative 
data diagnoses results 
against the results of 
the reference standard 
diagnoses:
describe the time interval 
and any interventions 
between administrative 
database diagnosis 
and reference standard 
diagnosis.
Signalling questions 
(yes/no/unclear)
Was a consecutive 
or random sample of 
patients enrolled?
Were the administrative 
database diagnosis 
results interpreted 
without knowledge of the 
results of the reference 
standard diagnosis?
Is the reference standard 
likely to correctly classify 
the epilepsy?
Was there an appropriate 
interval between 
administrative database 
diagnosis and reference 
standard diagnosis?
Was a case–control 
design avoided?
If a diagnostic threshold 
was used, was it 
prespecified?
Were the reference 
standard results 
interpreted without 
knowledge of the results 
of the administrative 
database diagnosis?
Did all patients receive a 
reference standard?
Did the study 
avoid inappropriate 
exclusions?
Did all patients receive the 
same reference standard?
Were all patients included 
in the analysis?
Risk of bias: high/
low/unclear
Could the selection 
of patients have 
introduced bias?
Could the conduct or 
interpretation of the 
administrative database 
have introduced bias?
Could the reference 
standard, its conduct or 
its interpretation have 
introduced bias?
Could the patient flow 
have introduced bias?
Concerns regarding 
applicability: high/
low/unclear
Are there concerns that 
the included patients 
do not match the review 
question?
Are there concerns 
that the administrative 
database, its conduct or 
interpretation differ from 
the review question?
Are there concerns that 
epilepsy, as defined by 
the reference standard, 
does not match the 
review question?
QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies 2.
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to record the information on which the judgement of 
applicability is made and then to rate their concern that 
the study does not match the review question.27 28
On completing the QUADAS-2 table, we will provide 
a risk of bias and applicability concerns graph demon-
strating the review authors’ judgements about each 
domain, presented as percentages across included 
studies. We will also provide a risk of bias and applica-
bility concerns summary demonstrating review authors’ 
judgements about each domain for each included study. 
We will use the Deek’s test29 to interrogate for publica-
tion bias. This test is specifically designed for detecting 
funnel plot asymmetry in reviews of diagnostic studies.28
Confidence in cumulative evidence
We will use the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) 
approach to assess strength of the body of evidence.30 
The GRADE system classifies the quality of evidence 
into one of four grades:
1. High: further research is very unlikely to change our 
conﬁdence in the estimate of effect.
2. Moderate: further research is likely to have an import-
ant impact on our conﬁdence in the estimate of effect 
and may change the estimate.
3. Low: further research is very likely to have an import-
ant impact on our confidence in the estimate of effect 
and is likely to change the estimate.
4. Very low: any estimate of effect is very uncertain.31
A judgement is made on the individual studies used 
to provide the pooled effect estimates, and the quality 
of evidence is then downgraded by the cumulative pres-
ence of: (1) bias (see risk of bias analysis), (2) incon-
sistency (ie, heterogeneity present on I2 statistic), (3) 
indirectness (ie, high concerns regarding applicability; 
see table 2), (4) imprecision (small sample sizes, wide 
CIs, and inadequately powered studies) and (5) publi-
cation bias (see Deek’s test29 comments).32 GRADE 
classifications will be independently conducted by two 
review authors (GKM and KB) with any disagreements 
resolved by mutual discussion and, where necessary, 
adjunction by a third reviewer (RFMC/SED/CRS).
We will rate the completeness of reporting for each 
study out of 30 using the STARD 2015 checklist.21 
A score of 0–10, 11–20 and 21–30 will indicate a low, 
moderate and high quality of completeness of reporting, 
respectively.
PAtIEnt And PublIC InvOlvEMEnt
Patients and the public were not involved in develop-
ment of the research question and outcome measures, 
nor the study design. The study does not involve patient 
recruitment, and patients were not involved in conduct 
of the study. We plan to liaise closely with patients, 
special interest groups, and charities in the dissemi-
nation of our results in printed and electronic media. 
Meta-data and information about the study will also be 
made available through our website (www. muirmaxwell-
centre. com).
Ethics and dissemination
Ethical approval is not required as primary data will not 
be collected. Results will be disseminated in peer-re-
viewed journals, conference presentations, and in press 
releases. Meta-data and information about the study will 
also be made available through our website (www. muir-
maxwellcentre. com) and via social media.
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